[go: up one dir, main page]

WO2002016355A3 - Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands - Google Patents

Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands Download PDF

Info

Publication number
WO2002016355A3
WO2002016355A3 PCT/US2001/022597 US0122597W WO0216355A3 WO 2002016355 A3 WO2002016355 A3 WO 2002016355A3 US 0122597 W US0122597 W US 0122597W WO 0216355 A3 WO0216355 A3 WO 0216355A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinuclidine
nicotinic
disease
treatment
substituted heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/022597
Other languages
French (fr)
Other versions
WO2002016355A2 (en
Inventor
Jason K Myers
Bruce N Rogers
Vincent E Groppi Jr
David W Piotrowski
Alice L Bodnar
Eric Jon Jacobsen
Jeffrey W Corbett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to EP01961664A priority Critical patent/EP1311505A2/en
Priority to JP2002521456A priority patent/JP2004506734A/en
Priority to AU2001282910A priority patent/AU2001282910A1/en
Publication of WO2002016355A2 publication Critical patent/WO2002016355A2/en
Publication of WO2002016355A3 publication Critical patent/WO2002016355A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compound of Formula (I): These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.
PCT/US2001/022597 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands Ceased WO2002016355A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01961664A EP1311505A2 (en) 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
JP2002521456A JP2004506734A (en) 2000-08-21 2001-08-17 Quinuclide-substituted heteroaryl moieties for disease treatment
AU2001282910A AU2001282910A1 (en) 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22665200P 2000-08-21 2000-08-21
US60/226,652 2000-08-21
US28483201P 2001-04-19 2001-04-19
US60/284,832 2001-04-19

Publications (2)

Publication Number Publication Date
WO2002016355A2 WO2002016355A2 (en) 2002-02-28
WO2002016355A3 true WO2002016355A3 (en) 2002-07-18

Family

ID=26920741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022597 Ceased WO2002016355A2 (en) 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands

Country Status (5)

Country Link
EP (1) EP1311505A2 (en)
JP (1) JP2004506734A (en)
AU (1) AU2001282910A1 (en)
PE (1) PE20020505A1 (en)
WO (1) WO2002016355A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10211416A1 (en) * 2002-03-15 2003-09-25 Bayer Ag New azabicycloalkyl carboxylic acid N-arylamides, are alpha 7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance
DE10211415A1 (en) * 2002-03-15 2003-09-25 Bayer Ag New azabicycloalkyl carboxylic acid N-biarylamides, are alpha-7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance
DE10234424A1 (en) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophene, benzofuran and indoleureas
WO2004052889A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
EP1587511A2 (en) * 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Treatment of diseases with alpha-7 nach receptor full agonists
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
SE0303076D0 (en) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
SE0303075D0 (en) * 2003-11-19 2003-11-19 Astrazeneca Ab 4-substituted imidazoles
EP1699787A1 (en) * 2003-12-22 2006-09-13 AstraZeneca AB Nicotinic acetylcholine receptor ligands
MXPA06007026A (en) * 2003-12-22 2006-08-31 Astrazeneca Ab Nicotinic acetylcholine receptor ligands.
JP2007538046A (en) 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ Novel azabicycloaryl derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
JP2009506037A (en) 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド Heteroaryl-substituted diazatricycloalkanes, methods for their preparation and methods for their use
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use
EP2182809B1 (en) 2007-08-27 2018-01-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
CN104193741B (en) 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 Quinuclidine-4-ylmethyl 1H-indole-3-carboxylic acid ester derivant as alpha 7 nicotinic acetylcholine receptor ligands
WO2009098282A1 (en) * 2008-02-06 2009-08-13 Novasaid Ab Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy
WO2009102962A2 (en) 2008-02-13 2009-08-20 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MA34957B1 (en) * 2011-02-23 2014-03-01 Lupin Ltd HETEROARYL DERIVATIVES AS MODULATORS OF NACHR ALPHA 7
ES2606043T3 (en) 2011-07-05 2017-03-17 Lupin Limited Biaryl derivatives as nAChR modulators
WO2013161871A1 (en) * 2012-04-25 2013-10-31 興和株式会社 Thiophene derivative having tlr-inhibiting activity
JPWO2014069554A1 (en) * 2012-10-31 2016-09-08 東レ株式会社 Quinuclidinamide derivative and its pharmaceutical use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327335A1 (en) * 1988-02-01 1989-08-09 Synthelabo Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency
EP0378111A1 (en) * 1989-01-09 1990-07-18 ZAMBON GROUP S.p.A. Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them
JPH04247081A (en) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5-membered heterocyclic acid amide
WO1997030998A1 (en) * 1996-02-23 1997-08-28 Astra Aktiebolag Azabicyclic esters of carbamic acids useful in therapy
WO1998054189A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
WO2001036417A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab New use and novel n-azabicyclo-amide derivatives
WO2001060821A1 (en) * 2000-02-18 2001-08-23 Astrazeneca Ab Novel biarylcarboxamides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327335A1 (en) * 1988-02-01 1989-08-09 Synthelabo Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency
EP0378111A1 (en) * 1989-01-09 1990-07-18 ZAMBON GROUP S.p.A. Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them
JPH04247081A (en) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5-membered heterocyclic acid amide
WO1997030998A1 (en) * 1996-02-23 1997-08-28 Astra Aktiebolag Azabicyclic esters of carbamic acids useful in therapy
WO1998054189A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
WO2001036417A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab New use and novel n-azabicyclo-amide derivatives
WO2001060821A1 (en) * 2000-02-18 2001-08-23 Astrazeneca Ab Novel biarylcarboxamides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANNON A W ET AL: "BROAD-SPECTRUM, NON-OPIOID ANALGESIC ACTIVITY BY SELECTIVE MODULATION OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, no. 5347, 1998, pages 77 - 81, XP000906771, ISSN: 0036-8075 *
HOLLADAY ET AL: "Neuronal Nicotinic Acetylcholine Receptros as Targets for Drug Discovery", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 26, 19 December 1997 (1997-12-19), pages 4169 - 4194, XP002124847, ISSN: 0022-2623 *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 025 (C - 1017) 18 January 1993 (1993-01-18) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity

Also Published As

Publication number Publication date
PE20020505A1 (en) 2002-06-12
WO2002016355A2 (en) 2002-02-28
JP2004506734A (en) 2004-03-04
AU2001282910A1 (en) 2002-03-04
EP1311505A2 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002016356A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
MXPA04004464A (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
WO2002100858A8 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
MXPA03011484A (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
WO2003070731A3 (en) Azabicyclic compounds for the treatment of disease
WO2004085433A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
MXPA04001500A (en) Compounds effecting glucokinase.
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2410234A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
WO2005018557A3 (en) Substituted pyridinones
WO2005082892A3 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
NO20052802L (en) Pyrrolopyrimidinderivativer
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2003006670A3 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
WO2005000815A3 (en) Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor
HK1053833A1 (en) Substituted phenyl farnesyltransferase inhibitors
PT992509E (en) NEW MACROLIDED DERIVATIVES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002521456

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001961664

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001961664

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001961664

Country of ref document: EP